Literature DB >> 34203890

NLRP7 Promotes Choriocarcinoma Growth and Progression through the Establishment of an Immunosuppressive Microenvironment.

Deborah Reynaud1,2, Roland Abi Nahed1,2, Nicolas Lemaitre1,2, Pierre-Adrien Bolze3, Wael Traboulsi4, Frederic Sergent1,2, Christophe Battail1,2, Odile Filhol1,2, Vincent Sapin5,6, Houssine Boufettal7, Pascale Hoffmann1,2,8, Touria Aboussaouira7, Padma Murthi9,10, Rima Slim11, Mohamed Benharouga1,2, Nadia Alfaidy1,2.   

Abstract

The inflammatory gene NLRP7 is the major gene responsible for recurrent complete hydatidiform moles (CHM), an abnormal pregnancy that can develop into gestational choriocarcinoma (CC). However, the role of NLRP7 in the development and immune tolerance of CC has not been investigated. Three approaches were employed to define the role of NLRP7 in CC development: (i) a clinical study that analyzed human placenta and sera collected from women with normal pregnancies, CHM or CC; (ii) an in vitro study that investigated the impact of NLRP7 knockdown on tumor growth and organization; and (iii) an in vivo study that used two CC mouse models, including an orthotopic model. NLRP7 and circulating inflammatory cytokines were upregulated in tumor cells and in CHM and CC. In tumor cells, NLRP7 functions in an inflammasome-independent manner and promoted their proliferation and 3D organization. Gravid mice placentas injected with CC cells invalidated for NLRP7, exhibited higher maternal immune response, developed smaller tumors, and displayed less metastases. Our data characterized the critical role of NLRP7 in CC and provided evidence of its contribution to the development of an immunosuppressive maternal microenvironment that not only downregulates the maternal immune response but also fosters the growth and progression of CC.

Entities:  

Keywords:  NLRP7; choriocarcinoma; hydatidiform mole; maternal immune tolerance; orthotopic model of choriocarcinoma; tumor microenvironment

Year:  2021        PMID: 34203890     DOI: 10.3390/cancers13122999

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  4 in total

1.  Case Report: First-Line Immune Checkpoint Inhibitor Plus Chemotherapy for Oral Metastasis in a Patient with Ultra High-Risk Gestational Choriocarcinoma.

Authors:  Yu Chen; Haiyan Ye; Jiming Tang; Yihan Weng; Jie Zhang; Jianhua Liu
Journal:  Cancer Manag Res       Date:  2022-06-03       Impact factor: 3.602

2.  The Placental NLRP3 Inflammasome and Its Downstream Targets, Caspase-1 and Interleukin-6, Are Increased in Human Fetal Growth Restriction: Implications for Aberrant Inflammation-Induced Trophoblast Dysfunction.

Authors:  Irvan Alfian; Amlan Chakraborty; Hannah E J Yong; Sheetal Saini; Ricky W K Lau; Bill Kalionis; Evdokia Dimitriadis; Nadia Alfaidy; Sharon D Ricardo; Chrishan S Samuel; Padma Murthi
Journal:  Cells       Date:  2022-04-21       Impact factor: 7.666

Review 3.  Role of NLRP7 in Normal and Malignant Trophoblast Cells.

Authors:  Roland Abi Nahed; Maya Elkhoury Mikhael; Deborah Reynaud; Constance Collet; Nicolas Lemaitre; Thierry Michy; Pascale Hoffmann; Frederic Sergent; Christel Marquette; Padma Murthi; Tiphaine Raia-Barjat; Nadia Alfaidy; Mohamed Benharouga
Journal:  Biomedicines       Date:  2022-01-24

4.  Epigenetic Dysregulation of Trophoblastic Gene Expression in Gestational Trophoblastic Disease.

Authors:  Zoltan Szabolcsi; Amanda Demeter; Peter Kiraly; Andrea Balogh; Melissa L Wilson; Jennifer R King; Szabolcs Hetey; Zsolt Gelencser; Koji Matsuo; Beata Hargitai; Paulette Mhawech-Fauceglia; Petronella Hupuczi; Andras Szilagyi; Zoltan Papp; Lynda D Roman; Victoria K Cortessis; Nandor Gabor Than
Journal:  Biomedicines       Date:  2021-12-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.